Showing 2091-2100 of 6810 results for "".
Strength in Numbers: Assessing Your Financial Position
https://practicaldermatology.com/topics/practice-management/strength-in-numbers-assessing-your-financial-position/23863/Look at your ratios and ranges to make sure you are keeping up with industry—and economic—shifts.Assessing the Pediatric Dermatology Workforce
https://practicaldermatology.com/topics/pediatric/assessing-the-pediatric-dermatology-workforce/23834/Physician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-4/23801/New Products
https://practicaldermatology.com/columns/new-products/new-products-4/23753/The Current Armamentarium of Topical Therapies to Treat Atopic Dermatitis and Psoriasis
https://practicaldermatology.com/topics/atopic-dermatitis/the-current-armamentarium-of-topical-therapies-to-treat-atopic-dermatitis-and-psoriasis/23748/A review of the alternatives to topical corticosteroids for managing common inflammatory skin diseases.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/Applying White Glove Service in the Practice
https://practicaldermatology.com/topics/practice-management/applying-white-glove-service-in-the-practice/23643/Help set your practice apart with these tips for providing unparalleled customer service to your patients.Unintended Consequences: Face Masks and Cosmetic Healing
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/unintended-consequences-face-masks-and-cosmetic-healing-1/23612/Wearing a face covering to reduce risk of COVID-19 may compromise healing from cosmetic surgery. Should lower face procedures be postponed?DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesPulse’s CellFX for Dermatologic Applications
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pulses-cellfx-for-dermatologic-applications/23464/A novel technology targets cells to treat warts, sebaceuous hyperplasia, and more.